TrialJournal of clinical pharmacology2017

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).

John P Gibbs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.